Prostate International Урология
Landmark-based stratification by at least 90% prostate-specific antigen decline and prostate-specific antigen nadir in androgen receptor pathway inhibitor–treated metastatic hormone-sensitive prostate cancer
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.